Efficacy and safety of febuxostat in Japanese paediatric patients with hyperuricaemia including gout: Phase 2, single arm, open‒label, multicentre studies
Modern Rheumatology · 2024
DOI: 10.1093/mr/roae056 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Shuichi Ito und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Kanagawa, Japan. Hauptthemen laut MEDLINE: Febuxostat, Hyperuricemia, Gout Suppressants, Gout. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
Urate-lowering efficacy and safety of febuxostat was evaluated in paediatric patients with hyperuricaemia including gout.
Methods
A Phase 2 study of febuxostat in paediatric patients aged 6–18 years with hyperuricaemia including gout was conducted. We evaluated the proportion of patients achieving serum uric acid (sUA) level ≤6.0 mg/dl at Week 26, and long-term safety and efficacy at Week 52. We also considered efficacy stratified by renal function.
Results
Thirty patients (10 at <40 kg and 20 at ≥40 kg) were enrolled. Twenty-four were males, 29 had asymptomatic hyperuricaemia, and 1 had gout. Age was 8 to 18 years. Of these, 63.3% (95% confidence interval 43.9–80.1%) achieved a sUA level of ≤6.0 mg/dl at Week 26. sUA level (mean ± standard deviation) was 5.55 ± 0.87 mg/dl, reduced from 9.01 ± 1.23 mg/dl at baseline. Febuxostat efficacy appeared similar for mild to moderate renal dysfunction and with normal renal function. There were no major safety issues.
Conclusions
In paediatric patients with hyperuricaemia including gout, febuxostat showed long-term, well-controlled urate-lowering efficacy with no major safety issues. Findings suggest that no dose adjustment is required for paediatric patients with mild to moderate renal dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Kanagawa, Japan.
- Clinical Development Department, Teijin Pharma Limited, Tokyo, Japan.
- Toxicology & DMPK Research Department, Teijin Institute for Bio-medical Research, Teijin Pharma Limited, Tokyo, Japan.
- Clinical Development Control Department, Teijin Pharma Limited, Tokyo, Japan.
- Rheumatology, Sanno Medical Center, Tokyo, Japan.
- Department of Rheumatology, International University of Health and Welfare, Chiba, Japan.
ORCID-Profile: Shuichi Ito
Zitieren
APA
Ito, S., Morita, Y., Nitami, M., Iwama, R., Nakajima, A., Yamanaka, H., & Honda, M. (2024). Efficacy and safety of febuxostat in Japanese paediatric patients with hyperuricaemia including gout: Phase 2, single arm, open‒label, multicentre studies. Modern Rheumatology. https://doi.org/10.1093/mr/roae056
Vancouver
Ito S, Morita Y, Nitami M, Iwama R, Nakajima A, Yamanaka H, et al. Efficacy and safety of febuxostat in Japanese paediatric patients with hyperuricaemia including gout: Phase 2, single arm, open‒label, multicentre studies. Modern Rheumatology. 2024. doi:10.1093/mr/roae056
BibTeX
@article{Ito2024,
author = {Ito, Shuichi and Morita, Yo and Nitami, Makoto and Iwama, Ryutaro and Nakajima, Akihiro and Yamanaka, Hisashi and Honda, Masataka},
title = {Efficacy and safety of febuxostat in Japanese paediatric patients with hyperuricaemia including gout: Phase 2, single arm, open‒label, multicentre studies},
journal = {Modern Rheumatology},
year = {2024},
doi = {10.1093/mr/roae056}
}
EUVIMED